Annovis Bio Inc. shares saw heightened volatility early Tuesday after the FDA approved the final protocol for its pivotal Phase 3 Alzheimer’s disease (AD) study, grabbing significant attention among retail investors.

MALVERN, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD),

Annovis Bio (NYSE:ANVS) announced Tuesday that the U.S. Food and Drug Administration (FDA) accepted an updated protocol for a pivotal Phase 3 trial for its Alzheimer's candidate, buntanetap. The study based on Phase 2/3 data for the oral small molecule in patients with early-stage Alzheimer's disease is expected to begin this month.